"FARMOVS is a South African clinical research organisation (CRO) that conducts ICH-GCP compliant Phase I to III clinical trials. Our competitive advantage is our wealth of bioequivalence and Phase I experience, clinical trial expertise and patient recruitment success through network-investigator sites managed by our Site Management Organisation (SMO) division. We, have a large clinical research facility with an on-site ISO 15189 accredited clinical laboratory and a GLP certified bioanalytical laboratory."

During the past decade, Farmovs-Parexel conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 9 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 7 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Farmovs-Parexel" #1 sponsor was "Allergan" with 4 trials, followed by "Bial - Portela C S.A." with 2 trials sponsored, "Cycle Pharmaceuticals Ltd." with 2 trials sponsored, "International Partnership for Microbicides, Inc." with 2 trials sponsored and "Merck KGaA, Darmstadt, Germany" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Farmovs-Parexel" #1 collaborator was "FARMOVS Clinical Research Organisation" with 2 trials as a collaborator, "Aegis Life, Inc." with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Centre national de recherche et de formation sur le paludisme (CNRFP)" with 1 trials as a collaborator and "Clinical Pharma Solutions Inc" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Farmovs-Parexel" are "Gastroparesis" (4 trials), "COVID-19" (3 trials), "Diabetes Mellitus" (3 trials), "Bioequivalence" (2 trials) and "Epilepsy" (2 trials). Many other conditions were trialed in "Farmovs-Parexel" in a lesser frequency.

Most popular intervention types in "Farmovs-Parexel" are "Drug" (15 trials), "Biological" (5 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Relamorelin" (3 trials), "AS902330" (2 trials), "BIA 2-093" (2 trials) and "Haloperidol Tablets, Cycle Pharmaceuticals Ltd" (2 trials). Other intervention names were less common.

The vast majority of trials in "Farmovs-Parexel" are 18 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Farmovs-Parexel". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Farmovs-Parexel, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Farmovs-Parexel, 14 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".